The Impact of Keynote-522 Related Iraes on Concurrent Adjuvant Whole Breast Radiotherapy in the Real World: A Case Series keynote-522 and adjuvant hypofractionated RT
Abstract
Background : In the KEYNOTE-522 study, a phase III, placebo-controlled trial, stage II-III triple negative breast cancer (TNBC) patients were randomized to receive neoadjuvant pembrolizumab versus placebo, plus paclitaxel and carboplatin for 4 cycles, followed by pembrolizumab versus placebo, plus cyclophosphamide and doxorubicin or epirubicin for 4 cycles. Adjuvant radiotherapy (RT) with standard fractionation was delivered concurrently to adjuvant pembrolizumab or 2 weeks before. No information on irradiated volumes, modalities, RT interruption duration were reported. Hypofractionated radiotherapy is the standard treatment but it was not allowed in this study. Thus published safety data don’t comply with real world practice.
Cases presentation: We present a case series of two consecutive TNBC patients developing acute toxicity during adjuvant moderate hypofractionated radiotherapy concomitant Pembrolizumab due to severe immune-related adverse events (irAEs). Both patients interrupted adjuvant RT definitively.
Conclusion: In KEYNOTE-522 the impact of irAEs on the RT adjuvant treatment was underestimated. In the real world the occurrence of irAEs during radiotherapy should be taken into account raising the question on timing of hypofractionated radiotherapy with new long course systemic therapy.
Full text article
References
Bentzen SM, Agrawal RK, Aird EG, Barret JM, Barrett-Lee PJ, Bliss JM et al. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9: 331-41. doi: 10.1016/S1470-2045(08)70077-9.
Bentzen SM, Agrawal RK, Aird EG, Barret JM, Barrett-Lee PJ, Bentzen SM et al. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371: 1098-107. doi: 10.1016/S0140-6736(08)60348-7
Whelan TJ, Pignol JP, Levine MN, Julian JA, Mackenzie R,Parpia S et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–20. doi: 10.1056/NEJMoa0906260.
Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M et al. Hypofractionated versus standard fractionated radiotherapy of 1882 patients with early breast cancer or ductal carcinoma in situ in the randomized phase III trial: the DBCG HYPO trial. J Clin Oncol 2020;38 (31) : 3615-25. doi: 10.1200/JCO.20.01363
Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A,Bloomfield DJ et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613-26. doi: 10.1016/S0140-6736(20)30932-6.
Van Hulle H, Vakaet V, Deckmyn K, Monten C, Paenlinck L, Van Grevelinck A et al. Two-year toxicity of hypofractionated breast cancer radiotherapy in five fractions. Acta Oncol 2020:872-75. doi: 10.1080/0284186X.2020.1747638.
Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol (2018) 8, 145- 52. doi: 10.1016/j.prro.2018.01.012
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J et al. Pembrolizumab for early triple negative breast cancer. New Engl J Med 2020;382:810–21. doi: 10.1056/NEJMoa1910549.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Annal Oncol 2021;32:1198–1200. doi: 10.1016/j.annonc.2021.06.014
Alcorn SR, Wright JL. Toxicity and Timing of Breast Radiation TherapyWith Overlapping Systemic Therapies. Int J Radiation Oncol Biol Phys, 2022; 114(3): 377−81. doi: 10.1016/j.ijrobp.2022.05.024.
Myer SP, Sevilimedu V, Jones VM, Abuhadra N, Montagna G, Plitas G et al. Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer. Ann Surg Oncol. 2024;31(8):5180-88. doi: 10.1245/s10434-024-15359-w
Tison T, Loap P, Arnaud E, Cao K, Bringer S,Kissel M et al. Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience. Advances in Radiation Oncology. 2024;9:101384. doi: 10.1016/j.adro.2023.101384
Colciago RR, Presti D, Giandini C, La Rocca E, Carnevale MG, Cavallo A et al. Safety of pembrolizumab with concurrent radiotherapy in early stage breast cancer: preliminary prospective real-world evidence. Research Square. 2024. doi.org/10.21203/rs.3.rs-4006571/v1.
Hendry JH, Bentzen SM, Dale RG, Fowler JF, Wheldon TE, Jones B, Munro AJ et al. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol. 1996; 8: 297–307. doi: 10.1016/s0936-6555(05)80715-0
Lazzari G, Benevento I, Montagna A, D’Andrea B, De Marco G, Castaldo G et al. Breast Cancer Adjuvant Radiotherapy in Up-Front to Chemotherapy: Is There a Worthwhile Benefit? A Preliminary Report. Breast Cancer: Targets and Therapy. 2024;16: 359–67. doi: 10.2147/BCTT.S471345
Liu Y, Hu Y, Xue J, Yi J, Bu J, Zhang Z et al. Advances in immunotherapy for triple-negative breast cancer. Molecular Cancer. 2023; 22:145. doi: 10.1186/s12943-023-01850-7.
Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L et al. Radiotherapy-exposed CD8 + and CD4 + neoantigens enhance tumor control. J Clin Invest . 2021; 131(5): e138740. doi: 10.1172/JCI138740.
Ho AY, Barker CA, Arnold BB, Powell SN, Hu ZI, Gucalp A et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer. 2020;126:850–60. doi: 10.1002/cncr.32599.
Wu J, Ni T, Deng R, Li Y, Zhong K, Tang Fet al. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. Front Immunol.2023; 14:1065510. doi: 10.3389/fimmu.2023.1065510
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncology. 2024 Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.